Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Armin Sepp

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
Journal of the Royal Society, Interface|July 8, 2025
Understanding antibody-target antigen interactions and the avidity effect using mathematical modellingLuke Heirene, Helen Byrne, Armin Sepp, et al.
CPT: Pharmacometrics & Systems Pharmacology|September 10, 2025
Modeling and Simulation Identifies Endocytosis Uptake Rate and Fraction Unbound as Important Predictors of Oligonucleotide PharmacokineticsFelix Stader, Abdallah Derbalah, Adriana Zyla, et al.
Journal of Pharmacokinetics and Pharmacodynamics|May 13, 2019
Computer-assembled cross-species/cross-modalities two-pore physiologically based pharmacokinetic model for biologics in mice and ratsArmin Sepp, Guy Meno-Tetang, Andrew Weber, et al.
Mabs|April 14, 2025
The physiological limits of bispecific monoclonal antibody tissue targeting specificityArmin Sepp, Felix Stader, Abdallah Derbalah, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|October 10, 2022
Application of physiologically based pharmacokinetic models for therapeutic proteins and other novel modalitiesRachel H Rose, Armin Sepp, Felix Stader, et al.
Antibodies (Basel, Switzerland)|August 27, 2024
A Physiologically Based Pharmacokinetic Model Relates the Subcutaneous Bioavailability of Monoclonal Antibodies to the Saturation of FcRn-Mediated Recycling in Injection-Site-Draining Lymph NodesFelix Stader, Cong Liu, Abdallah Derbalah, et al.
Journal of Pharmacokinetics and Pharmacodynamics|June 12, 2025
Cross-species translational modelling of targeted therapeutic oligonucleotides using physiologically based pharmacokineticsAbdallah Derbalah, Felix Stader, Cong Liu, et al.
Journal of Pharmacokinetics and Pharmacodynamics|July 30, 2025
Correction: Cross-species translational modelling of targeted therapeutic oligonucleotides using physiologically based pharmacokineticsAbdallah Derbalah, Felix Stader, Cong Liu, et al.
Mabs|April 21, 2016
Modeling bispecific monoclonal antibody interaction with two cell membrane targets indicates the importance of surface diffusionBram G Sengers, Sean McGinty, Fatma Z Nouri, et al.
Plos One|March 2, 2013
Liver-targeting of interferon-alpha with tissue-specific domain antibodiesEdward Coulstock, Jane Sosabowski, Milan Ovečka, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
Journal of the Royal Society, Interface|July 8, 2025
Understanding antibody-target antigen interactions and the avidity effect using mathematical modellingLuke Heirene, Helen Byrne, Armin Sepp, et al.
CPT: Pharmacometrics & Systems Pharmacology|September 10, 2025
Modeling and Simulation Identifies Endocytosis Uptake Rate and Fraction Unbound as Important Predictors of Oligonucleotide PharmacokineticsFelix Stader, Abdallah Derbalah, Adriana Zyla, et al.
Journal of Pharmacokinetics and Pharmacodynamics|May 13, 2019
Computer-assembled cross-species/cross-modalities two-pore physiologically based pharmacokinetic model for biologics in mice and ratsArmin Sepp, Guy Meno-Tetang, Andrew Weber, et al.
Mabs|April 14, 2025
The physiological limits of bispecific monoclonal antibody tissue targeting specificityArmin Sepp, Felix Stader, Abdallah Derbalah, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|October 10, 2022
Application of physiologically based pharmacokinetic models for therapeutic proteins and other novel modalitiesRachel H Rose, Armin Sepp, Felix Stader, et al.
Antibodies (Basel, Switzerland)|August 27, 2024
A Physiologically Based Pharmacokinetic Model Relates the Subcutaneous Bioavailability of Monoclonal Antibodies to the Saturation of FcRn-Mediated Recycling in Injection-Site-Draining Lymph NodesFelix Stader, Cong Liu, Abdallah Derbalah, et al.
Journal of Pharmacokinetics and Pharmacodynamics|June 12, 2025
Cross-species translational modelling of targeted therapeutic oligonucleotides using physiologically based pharmacokineticsAbdallah Derbalah, Felix Stader, Cong Liu, et al.
Journal of Pharmacokinetics and Pharmacodynamics|July 30, 2025
Correction: Cross-species translational modelling of targeted therapeutic oligonucleotides using physiologically based pharmacokineticsAbdallah Derbalah, Felix Stader, Cong Liu, et al.
Mabs|April 21, 2016
Modeling bispecific monoclonal antibody interaction with two cell membrane targets indicates the importance of surface diffusionBram G Sengers, Sean McGinty, Fatma Z Nouri, et al.
Plos One|March 2, 2013
Liver-targeting of interferon-alpha with tissue-specific domain antibodiesEdward Coulstock, Jane Sosabowski, Milan Ovečka, et al.
Pageof 3